Â
Walau sudah terbukti tidak berbahaya, menurut BPOM, vaksin ini sudah tidak digunakan lagi dalam program vaksinasi atau imunisasi dan tidak diedarkan lagi di Indonesia. Lembaga -- lembaga seperti BPOM, Kemenkes, KOMNAS PP KIPI juga berkomitmen untuk terus mengawasi peredaran segala macam vaksin sehingga tidak terjadi peningkatan efek samping akibat penggunaan vaksin.[6]
REFERENSI
-
Vaccines and immunization [Internet]. www.who.int. [cited 2024 May 25]. Available from: https://translate.google.com/translate?u=https://www.who.int/health-topics/vaccines-and-immunization&hl=id&sl=en&tl=id&client=srp&prev=search
Hutapea RU. AstraZeneca Tarik Vaksin COVID-19 di Seluruh Dunia [Internet]. detiknews. [cited 2024 May 9]. Available from: https://news.detik.com/internasional/d-7330401/astrazeneca-tarik-vaksin-covid-19-di-seluruh-dunia
AstraZeneca Tarik Vaksin Covid-19 dari Pasar Eropa usai Akui Adanya Efek samping Langka [Internet]. KOMPAS.tv. [cited 2024 May 9]. Available from: https://www.kompas.tv/internasional/506099/astrazeneca-tarik-vaksin-covid-19-dari-pasar-eropa-usai-akui-adanya-efek-samping-langka#google_vignette
Onyango J, Mukunya D, Napyo A, Nantale R, Makoko BT, Matovu JKB, et al. Side-Effects following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study. International Journal of Environmental Research and Public Health. 2022 Nov 19;19(22):15303.
Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) -COVID-19 Vaccine AstraZeneca (Other viral vaccines) [Internet]. 2021 [cited 2024 May 9]. Available from: https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid-19-vaccine-astrazeneca-other-viral-vaccines_en.pdf
Brandoctors. Penjelasan Publik | Badan Pengawas Obat dan Makanan [Internet]. Pom.go.id. 2024 [cited 2024 May 9]. Available from: https://www.pom.go.id/penjelasan-publik/penjelasan-publik-nomor-hm-01-1-2-05-24-35-tanggal-5-mei-2024-tentang-pemantauan-jangka-panjang-keamanan-vaksin-covid-19-astrazeneca